These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 33798642)

  • 41. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
    Kwon S; Ko H; You DG; Kataoka K; Park JH
    Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
    Gote V; Nookala AR; Bolla PK; Pal D
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer.
    Zhang J; Sun J; Li C; Qiao H; Hussain Z
    J Nanobiotechnology; 2023 Mar; 21(1):106. PubMed ID: 36964547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid generation of homogenous tumor spheroid microtissues in a scaffold-free platform for high-throughput screening of a novel combination nanomedicine.
    Abolhassani H; Zaer M; Shojaosadati SA; Hashemi-Najafabadi S
    PLoS One; 2023; 18(2):e0282064. PubMed ID: 36800370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment.
    Juan A; Cimas FJ; Bravo I; Pandiella A; Ocaña A; Alonso-Moreno C
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825618
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines.
    Valcourt DM; Kapadia CH; Scully MA; Dang MN; Day ES
    Adv Healthc Mater; 2020 Jun; 9(12):e2000110. PubMed ID: 32367687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
    Tracey SR; Smyth P; Barelle CJ; Scott CJ
    Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Smart Drug-Delivery Systems for Cancer Nanotherapy.
    Sanchez-Moreno P; Ortega-Vinuesa JL; Peula-Garcia JM; Marchal JA; Boulaiz H
    Curr Drug Targets; 2018 Feb; 19(4):339-359. PubMed ID: 27231107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
    Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
    Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nanomedicines Targeting the Tumor Microenvironment.
    Tong R; Langer R
    Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
    Lakshmanan VK
    Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging frontiers in nanomedicine targeted therapy for prostate cancer.
    Adekiya TA; Owoseni O
    Cancer Treat Res Commun; 2023; 37():100778. PubMed ID: 37992539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment.
    Singh A; Shafi S; Upadhyay T; Najmi AK; Kohli K; Pottoo FH
    Curr Top Med Chem; 2020; 20(20):1839-1854. PubMed ID: 32579503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanomedicine-Cum-Carrier by Co-Assembly of Natural Small Products for Synergistic Enhanced Antitumor with Tissues Protective Actions.
    Wang J; Zhao H; Qiao W; Cheng J; Han Y; Yang X
    ACS Appl Mater Interfaces; 2020 Sep; 12(38):42537-42550. PubMed ID: 32852938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imaging-assisted anticancer nanotherapy.
    Dasgupta A; Biancacci I; Kiessling F; Lammers T
    Theranostics; 2020; 10(3):956-967. PubMed ID: 31938045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer Nanomedicines Based on Synthetic Polypeptides.
    Sun H; Gu X; Zhang Q; Xu H; Zhong Z; Deng C
    Biomacromolecules; 2019 Dec; 20(12):4299-4311. PubMed ID: 31659901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.